Reduced methadone clearance during aromatase inhibition.
Methadone is increasingly used in pain management and is a cornerstone in the treatment of opiate withdrawal. It is subject to highly variable clearance among patients. The complete metabolic disposition of methadone is likely to involve a number of enzymes, including specifically CYP2B6. Previous studies in vitro suggest that metabolism by aromatase may also contribute. Single-dose methadone pharmacokinetics (2 mg, intravenous) were studied in 15 healthy postmenopausal women in the presence and absence of a potent aromatase inhibitor, letrozole. A sequential design was used, involving a control period followed by treatment with letrozole (2.5 mg/d, 11 days), in which each subject served as her own control. On average, letrozole treatment reduced methadone systemic clearance by 22% (P = 0.001), increased methadone AUC by 23% (P = 0.007), and increased elimination half-life by 21% (P = 0.042). The plasma parent-to-metabolite ratio also increased (P = 0.009), and there was a linear relationship (R2 = 0.74) between change in this plasma ratio and change in methadone AUC0-∞. In contrast, there was no such association with change in apparent urinary methadone clearance. Letrozole did not change methadone distribution half-life or its volume of distribution. Overall, these data demonstrate a significant decrease in methadone clearance during coadministration of letrozole, consistent with decreased metabolism brought about by aromatase inhibition. An involvement of aromatase in the disposition of methadone may help explain the difficulty in methadone dosing and suggests a broader role for this catalyst of endogenous steroid metabolism in xenobiotic drug disposition.
Division of Clinical Pharmacology, Indiana Institute for Personalized Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. lu20@iupui.edu
Wenjie Jessie
WJ
Lu
Nancy
N
Thong
David A
DA
Flockhart
D000368:Aged; D000701:Analgesics, Opioid / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D019540:Area Under Curve; D047072:Aromatase Inhibitors / Q000097:blood / Q000494:pharmacology*; D004347:Drug Interactions; D005260:Female; D006207:Half-Life; D006801:Humans; D000077289:Letrozole; D008657:Metabolic Clearance Rate / Q000187:drug effects; D008691:Methadone / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D008875:Middle Aged; D009570:Nitriles / Q000097:blood / Q000494:pharmacology*; D014230:Triazoles / Q000097:blood / Q000494:pharmacology*
D000701:Analgesics, Opioid; D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D000077289:Letrozole; D008691:Methadone